Trial: 201605141

ARST1431 – A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Phase

III

Principal Investigator

Huang, Frederick

Disease Site

Soft Tissue

Learn more about this study at: clinicaltrials.gov